FK Laboratories, a domestic biotech developer, is working on its novel drug candidate to prevent and treat thromboses, a serious health condition for millions of people.
Thrombosis is the formation of solid blood clots (thrombi) in the blood vessels which threatens to disrupt normal blood circulation. What poses the greatest threat to the human body in thrombus formation is a condition in which a thrombus suddenly breaks free from the wall of a vessel to become free-floating; it may get right into the heart or the lungs or the brain.
The drug candidate FK Laboratories has recently come up with represents the next generation of highly specific direct thrombin inhibitor, the solution most widely used to deal with the pathology. “The medicine under development is offering a range of key advantages, including oral administering, no toxicity, and high specificity,” said Elizaveta Rozhdestvenskaya, the executive director of Primer Capital, the fund that invested in the developer at the end of last year.
Currently thrombus-related pathology is said to be responsible for about 40% of adults’ premature deaths.